We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EVR:LSEEvraz PLC Analysis

Data as of 2026-03-12 - not real-time

$276.44

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Evercore Inc. (EVR) is trading at roughly $276, well below its DCF‑derived fair value of $851, implying a potential upside of over 40% and an undervalued positioning. The stock’s RSI of 30 suggests it is oversold, while the 20‑day SMA (≈$309) sits above the current price, pointing to short‑term support near $271. Fundamentally, revenue grew 32% YoY, gross margins remain exceptionally high at 93%, and operating margins are solid at 24.6%, delivering a ROE of 30%. The forward PE of 12 versus the industry average of 16 underscores a growth tilt, and a modest dividend yield of 1.17% with a low 23.6% payout ratio signals sustainability. Recent analyst sentiment has turned positive, highlighted by an upgrade to Zacks Rank 2 Buy, reinforcing the bullish narrative. However, the stock carries a high beta of 1.8 and 30‑day volatility near 51%, indicating heightened market sensitivity and a max drawdown of ~28% in recent history. Liquidity is stable but modest, with daily volumes around 300k shares. Overall, EVR offers a compelling blend of growth, value, and dividend appeal, but investors should weigh the elevated systematic risk.
Given these dynamics, the near‑term price action may test the $271 support before any upside move, while medium‑ to long‑term horizons remain attractive provided the firm sustains its margin profile and growth trajectory.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI at oversold levels (~30)
  • Price near technical support (~$271)
  • Sustainable dividend with low payout

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth (32% YoY)
  • Significant valuation upside (>40%)
  • Positive analyst upgrade to Zacks Rank 2 Buy

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • High ROE (30%) and robust margins
  • Undervalued relative to DCF fair value
  • Low dividend payout supporting cash generation

Key Metrics & Analysis

Financial Health

Revenue Growth32.20%
Profit Margin15.35%
P/E Ratio19.7
ROE30.07%
ROA13.44%
Debt/Equity49.79
P/B Ratio5.2
Op. Cash Flow$1.3B
Industry P/E16.4

Technical Analysis

TrendNeutral
RSI30.3
Support$270.91
Resistance$352.11
MA 20$309.29
MA 50$340.61
MA 200$314.51
MACDBearish
VolumeStable
Fear & Greed Index73.48

Valuation

Fair Value$850.95
Target Price$395.10
Upside/Downside42.93%
GradeUndervalued
TypeGrowth
Dividend Yield1.17%

Risk Assessment

Beta1.80
Volatility50.89%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.